AstraZeneca (LSE: AZN) on Wednesday said it has partnered with Japanese drug major Daiichi Sankyo (TYO: 4568) to develop and market its influenza vaccine in Japan.
The Anglo-Swedish drug major said it will receive an upfront payment from Daiichi Sankyo followed by development milestones and sales-related payments post launch. No financial details were disclosed.
Daiichi Sankyo will be responsible for all future development and marketing of FluMist Quadrivalent in Japan with AstraZeneca supplying the vaccine to Daiichi Sankyo.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze